Tinlarebant clinical trials
Also written LBS-008.
How each study uses tinlarebant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test tinlarebant, phase 3 first.
- Jun 2027Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyPhase 3 · Belite Bio, Inc
Studies
Open first, then newest update. How each study uses tinlarebant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseCompletedPhase 3Belite Bio, IncNCT05244304Written as Tinlarebant
- A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseActive, not recruitingPhase 2/3Belite Bio, IncNCT06388083Written as Tinlarebant
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyActive, not recruitingPhase 3Belite Bio, IncNCT05949593Written as Tinlarebant
- This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt DiseaseCompletedPhase 1/2RBP4 Pty LtdNCT05266014Written as tinlarebant
- Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85CompletedPhase 1RBP4 Pty LtdNCT05667688Written as Tinlarebant (LBS-008)
- Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy AdultsCompletedPhase 1Belite Bio, IncNCT04005807Written as BPN-14967
- Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple DosesCompletedPhase 1RBP4 Pty LtdNCT03735810Written as LBS-008
Codes
What other systems call tinlarebant · ClinicalTrials.gg INT015185
- UNII (FDA) 63WI9S8P1MTINLAREBANTOne source FDA
- NCI Thesaurus C171671TinlarebantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 63WI9S8P1M | TINLAREBANT | One source FDA |
| NCI Thesaurus | C171671 | Tinlarebant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.